IGF1 and acromegaly: Once-daily oral paltusotine demonstrated superior maintenance of biochemical control (IGF-I ≤ upper limit of normal [ULN]: 83.3% vs. 3.6%, p < 0.0001) and symptom control versus placebo in patients who switched from an injected SRL [50], achieved rapid and sustained biochemical and symptom improvement compared with placebo in previously untreated or treated/washed out patients with biochemically uncontrolled acromegaly [51], and was well tolerated.